Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

被引：112
作者：
Allen, Jeffrey A.
Adlakha, Ashish
Bergethon, Peter R.
机构：
[1] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA
[2] Tufts Univ New England Med Ctr, Dept Neurol, Boston, MA USA
来源：
ARCHIVES OF NEUROLOGY | 2006年 / 63卷 / 10期
关键词：
D O I：
10.1001/archneur.63.10.1475
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Objective: To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor. Design: Case report/literature review. Setting: University hospital. Patient: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma. Results: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab. Conclusions: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.
引用
收藏
页码：1475 / 1478
页数：4
相关论文
共 21 条
[1]   Posterior leukoencephalopathy without severe hypertension - Utility of diffusion-weighted MRI [J].
Ay, H ;
Buonanno, FS ;
Schaefer, PW ;
Le, DA ;
Wang, B ;
Gonzalez, RG ;
Koroshetz, WJ .
NEUROLOGY, 1998, 51 (05) :1369-1376
[2]   AUTONOMIC NERVES, MAST-CELLS, AND AMINE RECEPTORS IN HUMAN-BRAIN VESSELS - HISTOCHEMICAL AND PHARMACOLOGICAL STUDY [J].
EDVINSSON, L ;
OWMAN, C ;
SJOBERG, NO .
BRAIN RESEARCH, 1976, 115 (03) :377-393
[3]   Placental growth factor in the cerebrospinal fluid of women with preeclampsia [J].
Foyouzi, N ;
Norwitz, ER ;
Tsen, LC ;
Buhimschi, CS ;
Buhimschi, IA .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 92 (01) :32-37
[4]   Posterior leukoencephalopathy syndrome [J].
Garg, RK .
POSTGRADUATE MEDICAL JOURNAL, 2001, 77 (903) :24-28
[5]  
Glusker P, 2006, NEW ENGL J MED, V354, P980
[6]   Managing patients treated with bevacizumab combination therapy [J].
Gordon, MS ;
Cunningham, D .
ONCOLOGY, 2005, 69 :25-33
[7]   Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src [J].
He, H ;
Venema, VJ ;
Guo, XL ;
Venema, RC ;
Marrero, MB ;
Caldwell, RB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (35) :25130-25135
[8]   A reversible posterior leukoencephalopathy syndrome [J].
Hinchey, J ;
Chaves, C ;
Appignani, B ;
Breen, J ;
Pao, L ;
Wang, A ;
Pessin, MS ;
Lamy, C ;
Mas, JL ;
Caplan, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :494-500
[9]   MULTIFOCAL INFLAMMATORY LEUKOENCEPHALOPATHY WITH 5-FLUOROURACIL AND LEVAMISOLE [J].
HOOK, CC ;
KIMMEL, DW ;
KVOLS, LK ;
SCHEITHAUER, BW ;
FORSYTH, PA ;
RUBIN, J ;
MOERTEL, CG ;
RODRIGUEZ, M .
ANNALS OF NEUROLOGY, 1992, 31 (03) :262-267
[10]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
123